The Hidden Cost of Pill Form Weight Loss Drugs: What SNAC Is Doing Inside Your Gut

Scientists have discovered that salcaprozate sodium (SNAC), the ingredient that allows semaglutide to work as a pill, may be doing more inside your body than previously understood. In the first detailed animal study of its kind, researchers at Adelaide University found that SNAC was associated with changes in gut bacteria, inflammatory markers, and even brain-related proteins—raising new questions about the long-term safety of daily pill use as these medications become increasingly popular.

This discovery matters because the pill versions of Wegovy and Ozempic are becoming more accessible. The United States approved a tablet version of Wegovy late last year, and because pills are often seen as more convenient and potentially less expensive than injections, more people are likely to choose oral options over time. As usage expands globally, understanding every ingredient in these medications—not just the active drug—has become increasingly important.

What Did the SNAC Study Actually Find?

Researchers at Adelaide University conducted a 21-day animal study to systematically investigate how repeated exposure to SNAC affects the body. The findings revealed several notable biological changes that warrant closer examination:

• Gut Bacteria Decline: A reduction in beneficial gut bacteria that break down dietary fiber, which are essential for digestive health.
• Lower Protective Compounds: Decreased levels of short-chain fatty acids, which support the gut lining and help control inflammation throughout the body.
• Increased Inflammation: Higher levels of inflammatory markers detected in the blood, suggesting systemic inflammation may be triggered.
• Liver Changes: Greater liver weight, which researchers interpret as a possible sign of low-grade inflammation in this organ.
• Intestinal Shrinkage: A smaller cecum—the part of the intestine where gut bacteria break down fiber and produce protective compounds.
• Brain Protein Reduction: Reduced levels of a brain-derived protein associated with cognitive function.

Lead researcher Amin Ariaee, a PhD candidate at Adelaide University, emphasized the importance of understanding these findings in context. "Obesity is a complex, chronic disease with serious health consequences. These medicines are highly effective and are helping many people," Ariaee says. "But as oral versions become more widely used, we need to understand what repeated, long-term exposure to all ingredients in the pill means for the body—not just the active drug".

Does This Mean SNAC Is Harmful?

The short answer: not necessarily, but the question deserves serious investigation. The study does not prove that SNAC causes harm in humans. However, it does show that the ingredient enabling these tablets to work may have biological effects that extend beyond its intended role of helping semaglutide survive stomach acid and enter the bloodstream.

Dr. Paul Joyce, a senior research fellow at Adelaide University, stressed the importance of caution in interpreting these findings. "Importantly, our findings do not prove that SNAC causes harm in humans," Dr. Joyce explains. "However, they do show that the ingredient enabling these tablets to work may have adverse biological effects beyond drug absorption. These medicines are typically taken daily and often for long periods. As their use expands globally, it becomes increasingly important to evaluate all components of these therapies, not just the active compound".

How to Stay Informed About Weight Loss Medication Safety

• Ask Your Doctor About Formulation: When discussing semaglutide or tirzepatide with your healthcare provider, ask whether the injection or pill form is more appropriate for your situation, and discuss any concerns about long-term ingredient exposure.
• Monitor Your Gut Health: Pay attention to changes in digestion, bloating, or gastrointestinal symptoms while taking these medications, and report any new or worsening symptoms to your doctor promptly.
• Stay Updated on Research: Follow emerging studies on GLP-1 medications and their ingredients, as new safety data continues to emerge and regulatory agencies update warnings based on real-world evidence.
• Discuss Individual Risk Factors: Talk with your healthcare provider about your personal health history, including any existing gut issues or inflammatory conditions, to determine if these medications are right for you.

The Bigger Picture: Safety Concerns Beyond SNAC

The SNAC discovery comes at a time when semaglutide-based medications are facing increased scrutiny from multiple angles. Lawyers across the country are investigating lawsuits related to Ozempic, Wegovy, and related drugs, with over 3,000 product liability cases now pending in federal court. The focus of litigation has shifted significantly from gastroparesis (stomach paralysis) to vision loss, particularly a rare eye condition called non-arteritic anterior ischemic optic neuropathy (NAION) that can cause sudden vision loss.

In March 2026, the United Kingdom's Medicines and Healthcare products Regulatory Agency issued a safety update warning that semaglutide may be linked in rare cases to NAION, a condition that affects the optic nerve and typically causes sudden, painless loss of vision in one eye. Patients experiencing sudden or rapidly worsening eyesight while taking the drug are being advised to seek urgent medical attention.

Meanwhile, the competitive landscape for weight loss medications is shifting rapidly. Eli Lilly's tirzepatide-based drugs—Zepbound for weight loss and Mounjaro for type 2 diabetes—have been outperforming Novo Nordisk's semaglutide products in recent clinical trials. In one head-to-head study, Zepbound delivered 25.5% weight loss at 84 weeks compared to 23% with Novo Nordisk's next-generation candidate, CagriSema. This competitive pressure has prompted Novo Nordisk to announce steep price cuts for its three largest revenue drivers—Wegovy, Ozempic, and Rybelsus—lowering them to $675 per month starting in January 2027.

What This Means for People Using These Medications

If you're currently taking a pill form of semaglutide or considering it, the SNAC findings don't necessarily mean you should stop or avoid the medication. Rather, they underscore the importance of informed decision-making with your healthcare provider. The medications have proven effective for weight loss and improving metabolic health in millions of people worldwide. However, as these drugs become more widely used and available in pill form, ongoing research into all their components—not just the active ingredient—becomes increasingly valuable.

The Adelaide University study represents the kind of rigorous investigation that helps ensure patients and doctors have complete information about what they're putting into their bodies. As obesity remains a major global health issue affecting roughly one in eight people worldwide, and with 43% of Americans age 15 and older living with obesity, the stakes for understanding these medications fully are high.

The bottom line: these weight loss medications are helping many people achieve significant health improvements. But as their use expands and new formulations become available, staying informed about emerging research—including findings about seemingly minor ingredients like SNAC—is an essential part of making the best choice for your health.